NCT06708936撤回1 期
A Single-arm, Open-label, Single-center, Multiple-dose Early Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KSD-201 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Kousai Bio Co., Ltd.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- DLT
研究概览
简要总结
The main purpse of this study is to evaluate the safety and tolerability of KSD-101 in patients with advanced clear cell renal cell carcinoma, to evaluate the initial clinical outcomes , immune response, and to evaluate the impact of KSD-201 on the quality of life in patients with advanced clear cell renal cell carcinoma.
详细描述
This study is a single-center, single-arm, open-label, dose-confirmation clinical trial designed to evaluate the safety, tolerability, immune response, and preliminary clinical efficacy of KSD-201 in the treatment of patients with advanced clear cell renal cell carcinoma. The study is conducted in two phases: the first phase is for dose-limiting toxicity (DLT) observation and dose confirmation; the second phase is an expansion study, where the investigators may add 3 to 6 subjects based on the safety and efficacy signals obtained from the first phase.
Enrolled subjects will undergo peripheral blood mononuclear cell collection. The collected material is transported via cold chain logistics to the dendritic cell vaccine preparation site, where the dendritic cell vaccine (KSD-201) is prepared using the subject's own monocytes. Once KSD-201 is successfully prepared, subjects will return to the hospital for KSD-201 injection according to the following method.
- KSD-201 treatment dose: The provisional dosing is set at 5.0 × 10^6 cells/dose.
- KSD-201 treatment frequency: a total of 3-5 times. The 4th and 5th times are booster treatments, which need to be decided by the investigator according to the condition of the subjects.
- Dosing interval: 2 weeks. The interval may be adjusted based on the subject's condition during the intensive treatment phase.
- KSD-201 route of administration: subcutaneous injection.
- Administration site: near the axillary lymph node or inguinal lymph node.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Subjects and/or their legal guardians agree to participate and sign the ICF.
- •Male or female subjects aged 18 years and above on the day of ICF signing.
- •Patients with advanced clear cell renal cell carcinoma, confirmed by pathological tissue examination, who have failed standard therapy (failure of standard therapy refers to disease progression confirmed by imaging during or after at least one systemic regimen, or intolerance to such regimen, which includes tyrosine kinase inhibitors such as sunitinib, axitinib, pazopanib, sorafenib, among others, as well as everolimus and immune checkpoint inhibitors), and for whom no effective treatment measures are available, with the condition posing a serious threat to their lives.
- •4. According to RECIST v1.1 criteria, there should be at least one measurable lesion.
- •5. Eastern Cooperative Oncology Group (ECOG) score of 0-
- •Eligible for leukapheresis and has no other contraindications for cell collection.
- •7. Must have adequate organ function：
- •Hematology test: Monocyte count ≥ 0.1 × 10^9/L, neutrophil count ≥ 1.5 × 10^9/L, hemoglobin ≥ 90 g/L, platelet count ≥ 100 × 10^9/L， and no blood transfusion or blood products within 28 days prior to leukapheresis, and no use of hematopoietic growth factors or other drugs to correct blood cells.
- •Liver function: ALT, AST ≤ 2.5 × ULN and TBIL ≤ 1.5 × ULN [for patients with liver metastases: ALT, AST ≤ 5 × ULN and TBIL ≤ 2 × ULN]
- •Kidney function: Creatinine ≤ 1.5 × ULN
- •Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%
- •pulmonary function：Pulse oximetry saturation ≥ 94%.
- •Coagulation function: Fibrinogen ≥ 1.0 g/L, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN, prothrombin time (PT) ≤ 1.5 × ULN
- •Patient's corresponding lymph node regions meet the requirements for subcutaneous injection.
- •9. Male and female subjects of reproductive age agree to take non-pharmacological contraceptive measures from signing the ICF until 6 months after the last dose.
排除标准
- •1. Within 4 weeks prior to apheresis, patients have received any chemotherapy, immunosuppressive drugs, or other medicinal treatments, or have undergone less than 5 drug half-lives (whichever is shorter), and within 2 weeks prior to apheresis, they have undergone systemic radiation therapy.
- •2. Underwent allogeneic transplantation prior to enrollment.
- •Received (attenuated) live vaccines within 4 weeks prior to enrollment.
- •Participated in other clinical studies within 4 weeks prior to enrollment and received at least one dose of the investigational product.
- •5. Underwent therapeutic surgery within 4 weeks prior to enrollment, or plan to undergo major surgery during the study, except diagnostic, biopsy and drainage procedures.
- •6. Presence of uncontrolled infectious disease within 4 weeks prior to enrollment.
- •7. Receiving systemic corticosteroid therapy prior to screening and require long-term systemic corticosteroids during the treatment period (except inhalation or topical application) as judged by the investigator, or received systemic corticosteroid therapy (except inhalation or topical application) within 72 hours prior to administration.
- •8. Active central nervous system metastases/lesions (e.g., brain edema requiring hormone intervention or brain metastases).
- •9. Severe cardiovascular diseases:
- •Grade ≥ 3 cardiovascular diseases according to the New York Heart Association (NYHA) classification within 6 months prior to enrollment.
- •Unstable angina or severe arrhythmias requiring medication.
- •Other significant ECG abnormalities, including second-degree type 2 atrioventricular block, third-degree atrioventricular block, bradycardia (ventricular rate < 50 beats/min with clinical symptoms), etc.
- •10. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and increased peripheral blood hepatitis B virus (HBV) DNA titer above the ULN; positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis-specific antibodies.
- •11. Have not recovered to normal or Grade ≤ 1 from prior treatment-induced AEs prior to enrollment, except alopecia (any grade) and peripheral neuropathy (Grade ≤ 2).
- •12. Other active malignancies within the past 3 years, except for curable cancers that have been markedly cured, such as basal or squamous cell carcinoma, cervical or breast cancer in situ.
- •13. Prior history of severe drug allergies or history of penicillin allergy.
- •Substance abuse/addiction.
- •Women who are pregnant or nursing.
- •Other serious medical conditions, including liver disease, kidney disease, neurological/psychiatric disorders, endocrine disorders, hematologic disorders, and immune system disorders, which will render a subject unsuitable for participation in the study as judged by the investigator.
- •17. Other conditions that render a subject unsuitable for enrollment as judged by the investigator.
研究组 & 干预措施
KSD-201
Experimental
Biological: Dendritic Cell Vaccine.Autologous monocyte-derived DCs pulsed with clear cell renal cell carcinoma-associated antigen.
干预措施: KSD-201 (Biological)
结局指标
主要结局
DLT
时间窗: From the infusion (Day 0) to Day 28
Incidence and number of dose-limiting toxicities
Safety
时间窗: 1 year after DC Vaccines injection
Incidence and severity of AEs, including vital signs, physical examination, and laboratory tests
次要结局
- Objective response rate (ORR)(1 year after DC Vaccines injection)
- Disease control rate (DCR)(1 year after DC Vaccines injection)
- Duration of response (DOR)(1 year after DC Vaccines injection)
- Progression-free survival (PFS)(1 year after DC Vaccines injection)
- Overall survival (OS)(1 year after DC Vaccines injection)
- Levels of various lymphocyte subsets(1 year after DC Vaccines injection)
- EQ-5D-5L(Up to 1 year)
- QLQ-C30(Up to 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
1 期
KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical TrialEBV-associated Haematologic NeoplasmsNCT05635591Tongji Hospital9
已完成
1 期
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male SubjectsDrug ToxicityNCT01979380Kwang Dong Pharmaceutical co., ltd.40
Unknown
1 期
To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight SubjectsObesityNCT02462031Kwang Dong Pharmaceutical co., ltd.38
已完成
1 期
Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate DrugsArthritisNCT03876210PMG Pharm Co., Ltd47
撤回
早期 1 期
KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical TrialEBV-associated LymphomasNCT05882305Kousai Bio Co., Ltd.9